Company: RPTX
Filing Date: 2025-11-14
Form Type: DEFA14A
Source: 0001193125-25-283320
Chunk: 1

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-14
Form: DEFA14A
Chunk 1
---
 chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition. On November 14, 2025, Repare Therapeutics Inc. (the “Company”) issued a press release announcing its recent business highlights, financial results for the three and nine months ended September 30, 2025 and other events described under Item 8.01 hereto. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as described under Item 8.01 hereto or as shall be expressly set forth by specific reference in such filing. Item 8.01 Other Events. On November 14, 2025, the Company announced that it has entered into a definitive arrangement agreement (the “Arrangement Agreement”) with XenoTherapeutics, Inc., a Massachusetts non-profitcorporation (“Parent”) and Xeno Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Parent (together with Parent, “Xeno”), pursuant to which Xeno will acquire all of the issued and outstanding common shares of the Company (the “Transaction”). The press release announcing the execution of the Arrangement Agreement is attached hereto as Exhibit 99.1 and is incorporated by reference herein, excluding any information regarding financial results for the three and nine months ended September 30, 2025 or Company business highlights not related to the Transaction. Additional information required to be reported on a Current Report on Form 8-Kwith respect to the Transaction will be filed by the Company in a subsequent Current Report on Form 8-K. Additional Information and Where to Find It The Company intends to file with the Securities Exchange Commission (“SEC”) and furnish to its shareholders a proxy statement on Schedule 14A, as well as other relevant documents concerning the Transaction. The proxy statement will contain important information about the Transaction and related matters, including information related to a special meeting of shareholders to be held by the Company seeking required approvals from the Company’s shareholders in